Skip to main content
Top
Published in: Respiratory Research 1/2015

Open Access 01-12-2015 | Research

Lung function, symptoms and inflammation during exacerbations of non-cystic fibrosis bronchiectasis: a prospective observational cohort study

Authors: Simon E Brill, Anant RC Patel, Richa Singh, Alexander J Mackay, Jeremy S Brown, John R Hurst

Published in: Respiratory Research | Issue 1/2015

Login to get access

Abstract

Background

Exacerbations of non-cystic fibrosis bronchiectasis cause significant morbidity but there are few detailed data on their clinical course and associated physiological changes. The biology of an exacerbation has not been previously described.
The purpose of this study was to describe changes in lung function, symptoms, health status and inflammation during the development and recovery from community-treated exacerbations.

Methods

This was a prospective observational cohort study of 32 outpatients with non-cystic fibrosis bronchiectasis conducted between August 2010 and August 2012. Patients completed a symptom diary card and measured their peak expiratory flow rate (PEFR) daily. Exacerbations were defined as oral antibiotic treatment taken for a worsening of respiratory symptoms. Symptoms and peak flow at exacerbation were analysed, and further measurements including the COPD Assessment Test (CAT) and inflammatory markers were also compared to baseline values.

Results

At baseline, health status was significantly related to lung function, prognostic severity and systemic inflammation. 51 exacerbations occurred in 22 patients. Exacerbation symptoms began a median (interquartile range) of 4 (2, 7) days before treatment started and the median exacerbation duration was 16 (10, 29) days. 16% had not recovered by 35 days. At exacerbation, mean PEFR dropped by 10.6% (95% confidence interval 6.9-14.2, p < 0.001) and mean CAT score increased by 6.3 units (3.6-9.1, p = 0.001), median symptom count by 4 (2.25, 6, p < 0.001), and mean CRP by 9.0mg/L (2.3-15.8, p = 0.011). Exacerbations where PEFR fell by ≥10% were longer with more symptoms at onset.

Conclusion

Exacerbations of non-CF bronchiectasis are inflammatory events, with worsened symptoms, lung function and health status, and a prolonged recovery period. Symptom diary cards, PEFR and CAT scores are responsive to changes at exacerbation and may be useful tools for their detection and monitoring.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pasteur MC, Bilton D, Hill AT. British thoracic society guideline for non-CF bronchiectasis. Thorax. 2010;65 Suppl 1:i1–58.CrossRefPubMed Pasteur MC, Bilton D, Hill AT. British thoracic society guideline for non-CF bronchiectasis. Thorax. 2010;65 Suppl 1:i1–58.CrossRefPubMed
2.
go back to reference Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005;12:205–9.CrossRef Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005;12:205–9.CrossRef
3.
go back to reference Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respir Med. 2010;104:981–5.CrossRefPubMed Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respir Med. 2010;104:981–5.CrossRefPubMed
4.
go back to reference De Soyza A, Brown JS, Loebinger MR. Research priorities in bronchiectasis. Thorax. 2013;68:695–6.CrossRefPubMed De Soyza A, Brown JS, Loebinger MR. Research priorities in bronchiectasis. Thorax. 2013;68:695–6.CrossRefPubMed
5.
go back to reference Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): A randomised, double-blind, placebo-controlled trial. Lancet. 2012;380:660–7.CrossRefPubMed Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): A randomised, double-blind, placebo-controlled trial. Lancet. 2012;380:660–7.CrossRefPubMed
6.
go back to reference Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, Van Haren EHJ, Koppers RJH, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: The BAT randomized controlled trial. J Am Med Assoc. 2013;309:1251–9.CrossRef Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, Van Haren EHJ, Koppers RJH, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: The BAT randomized controlled trial. J Am Med Assoc. 2013;309:1251–9.CrossRef
7.
go back to reference Brill SE, Bruce-Hickman D, Leith DJ, Singh R, Mackay AJ, Patel ARC, et al. The biology of a bronchiectasis exacerbation: changes in daily peak expiratory flow rate and symptoms before, during and afterwards. Thorax. 2013;68 Suppl 3:A123.CrossRef Brill SE, Bruce-Hickman D, Leith DJ, Singh R, Mackay AJ, Patel ARC, et al. The biology of a bronchiectasis exacerbation: changes in daily peak expiratory flow rate and symptoms before, during and afterwards. Thorax. 2013;68 Suppl 3:A123.CrossRef
8.
go back to reference Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.CrossRefPubMed Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.CrossRefPubMed
9.
go back to reference Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Kline LN. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34:648–54.CrossRefPubMed Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Kline LN. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34:648–54.CrossRefPubMed
10.
go back to reference Wilson CB, Jones PW, O’Leary CJ, Cole PJ, Wilson R. Validation of the St. George’s Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med. 1997;156:536–41.CrossRefPubMed Wilson CB, Jones PW, O’Leary CJ, Cole PJ, Wilson R. Validation of the St. George’s Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med. 1997;156:536–41.CrossRefPubMed
11.
go back to reference Bhalla M, Turcios N, Aponte V, Jenkins M, Leitman BS, McCauley DI, et al. Cystic fibrosis: scoring system with thin-section CT. Radiology. 1991;179:783–8.CrossRefPubMed Bhalla M, Turcios N, Aponte V, Jenkins M, Leitman BS, McCauley DI, et al. Cystic fibrosis: scoring system with thin-section CT. Radiology. 1991;179:783–8.CrossRefPubMed
12.
go back to reference Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The Bronchiectasis Severity Index: An international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576–85.CrossRefPubMedPubMedCentral Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The Bronchiectasis Severity Index: An international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576–85.CrossRefPubMedPubMedCentral
13.
go back to reference Reddel HK, Salome CM, Peat JK, Woolcock AJ. Which index of peak expiratory flow is most useful in the management of stable asthma? Am J Respir Crit Care Med. 1995;151:1320–5.CrossRefPubMed Reddel HK, Salome CM, Peat JK, Woolcock AJ. Which index of peak expiratory flow is most useful in the management of stable asthma? Am J Respir Crit Care Med. 1995;151:1320–5.CrossRefPubMed
14.
go back to reference Hill AT, Flume PA. Lung clearance index. A potential quantitative tool to assess treatment response in bronchiectasis? Am J Respir Crit Care Med. 2014;189(5):510–1.CrossRefPubMed Hill AT, Flume PA. Lung clearance index. A potential quantitative tool to assess treatment response in bronchiectasis? Am J Respir Crit Care Med. 2014;189(5):510–1.CrossRefPubMed
15.
go back to reference Rowan SA, Bradley JM, Bradbury I, Lawson J, Lynch T, Gustafsson P, et al. Lung clearance index is a repeatable and sensitive indicator of radiological changes in bronchiectasis. Am J Respir Crit Care Med. 2014;189(5):586–92.CrossRefPubMed Rowan SA, Bradley JM, Bradbury I, Lawson J, Lynch T, Gustafsson P, et al. Lung clearance index is a repeatable and sensitive indicator of radiological changes in bronchiectasis. Am J Respir Crit Care Med. 2014;189(5):586–92.CrossRefPubMed
16.
go back to reference Mackay AJ, Donaldson GC, Patel AR, Jones PW, Hurst JR, Wedzicha JA. Usefulness of the chronic obstructive pulmonary disease assessment test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med. 2012;185:1218–24.CrossRefPubMed Mackay AJ, Donaldson GC, Patel AR, Jones PW, Hurst JR, Wedzicha JA. Usefulness of the chronic obstructive pulmonary disease assessment test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med. 2012;185:1218–24.CrossRefPubMed
17.
go back to reference Lee BY, Lee S, Lee JS, Song JW, Lee SD, Jang SH, et al. Validity and reliability of CAT and dyspnea-12 in Bronchiectasis and Tuberculous destroyed lung. Tuberc Respir Dis (Seoul). 2012;72(6):467–74.CrossRef Lee BY, Lee S, Lee JS, Song JW, Lee SD, Jang SH, et al. Validity and reliability of CAT and dyspnea-12 in Bronchiectasis and Tuberculous destroyed lung. Tuberc Respir Dis (Seoul). 2012;72(6):467–74.CrossRef
18.
go back to reference Kon SSC, Canavan JL, Jones SE, Nolan CM, Clark AL, Dickson MJ, et al. Minimum clinically important difference for the COPD assessment test: a prospective analysis. Lancet Respir Med. 2014;2(3):195–203.CrossRefPubMed Kon SSC, Canavan JL, Jones SE, Nolan CM, Clark AL, Dickson MJ, et al. Minimum clinically important difference for the COPD assessment test: a prospective analysis. Lancet Respir Med. 2014;2(3):195–203.CrossRefPubMed
19.
go back to reference Loebinger MR, Shoemark A, Berry M, Kemp M, Wilson R. Procalcitonin in stable and unstable patients with bronchiectasis. Chron Respir Dis. 2008;5:155–60.CrossRefPubMed Loebinger MR, Shoemark A, Berry M, Kemp M, Wilson R. Procalcitonin in stable and unstable patients with bronchiectasis. Chron Respir Dis. 2008;5:155–60.CrossRefPubMed
Metadata
Title
Lung function, symptoms and inflammation during exacerbations of non-cystic fibrosis bronchiectasis: a prospective observational cohort study
Authors
Simon E Brill
Anant RC Patel
Richa Singh
Alexander J Mackay
Jeremy S Brown
John R Hurst
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2015
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-015-0167-9

Other articles of this Issue 1/2015

Respiratory Research 1/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.